Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 1300 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Estimated Study Start Date: November 30, 2019
Estimated Primary Completion Date: September 30, 2023
Estimated Study Completion Date: September 30, 2023

Arm:
- Experimental: Nemolizumab